AMINVESTMENT BANK RESEARCH (MAY 24): The drag from associated company Straits Apex Sdn Bhd (SA) is expected to ease in the coming quarters. Major customer Smith and Nephew Sales Sdn Bhd, which contributes to about 62% of SA sales, performed the bulk of 1QFY21’s transactions in 4QFY20. Pandemic uncertainty has also led it to delay the bulk of its remaining orders to 2HFY21. Currently, order levels are similar to last year’s.
However, poor utilisation rates at SPP NOVO are expected to keep manufacturing segment margins depressed; therefore, the group is deferring expansion plans until pharmaceutical demand returns.
Meanwhile, rising freight and raw material costs are likely to compress margins in the coming quarters. While ASPs for group brand products remain unchanged, they may rise in the coming quarters. External products have already seen a 6% increase in ASP.
With the Ministry of Health’s (MoH) expenses tied up by the pandemic’s resurgence, the group believes government tenders are hard to come by at the moment. We expect this to normalise in FY22F, as the bulk of the MoH’s mass vaccinations will have already been completed by then. Going forward, we remain positive on Apex’s future prospects as a recovery play.
Political instability always presents the best opportunities to buy the dips. When everyone's attention is grabbed by glove companies, it is the perfect chance to buy in alternative healthcare and pharmaceutical companies. And for what's worth, Apex Healthcare is a well-managed company
21 years ago, AHEALTH was first listed on the Second Board with around 100 mil in market capitalisation. 21 years later, AHEALTH became one of the most consistent profitable companies on Bursa Main Market with about 1 bil in market capitalisation.
Hats off to such an outstanding Malaysian company. May the next 21 years be even better.
They are investing a lot into production, machine and factories hence less money to be given out as dividends. The share is non-speculative due to most of the holdings are held by the directors and owners. Hence it is very hard to goreng shares like this. These are the "Tanker" shares, they can easily tank recession and outlast the smallcap counters.
If you prefer gambling and speculative shares, you're better off buying penny stocks as those have almost 0 returns and price swing wildly due to rumours and speculation. Depending on which type of investor you are, some people prefer insurance and banking, some people prefer healthcare, some prefer energy, some people just follow the wind and hype according to what come out in the newspaper during the moment.. Price movement may be boring, but this is for slow and steady, keep for long term or retirement kind like bank shares.
My take is, the share hasn't seen any bonus in over 10 years. They have grown steadily in terms of asset. Hence, I foresee they may issue bonus eventually when the industry recovers and we are in better financial situation. It's not like they're having debt problems or not-profitable. The share price is just boring cause most of the shareholding held by the owners and directors, so there is not enough public shares for operators to goreng.
Apex Healthcare Bhd said it has inked an agreement with Innova Bio-Medical Pte Ltd to supply the Sinopharm Covid-19 vaccine to private healthcare practitioners in Singapore. Innova is part of the Innova Medical Group, a global company specializing in innovative screening, testing and diagnostics for cancer, heart disease, arterial calcification, stroke, and virus detection focused on infectious diseases. Under the deal, Innova will supply the Chinese-made vaccine to Apex’s wholly-owned unit in Singapore, Apex Pharma Marketing Pte Ltd, for onward sale and distribution to hospitals and private clinics within the city state, said Apex Healthcare.
people expected AHEALTH would get the benefit when the pandemic started. Unfortunately its revenue and profit have been so-so for 6 quarters. Disappointed. it will not surprise me if its share price is going back to the price before the pandemic.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....